381 related articles for article (PubMed ID: 31052499)
21. Serological reactivity of baculovirus-expressed Ebola virus VP35 and nucleoproteins.
Groen J; van den Hoogen BG; Burghoorn-Maas CP; Fooks AR; Burton J; Clegg CJ; Zeller H; Osterhaus AD
Microbes Infect; 2003 Apr; 5(5):379-85. PubMed ID: 12737993
[TBL] [Abstract][Full Text] [Related]
22. The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development.
Zhu W; Banadyga L; Emeterio K; Wong G; Qiu X
Viruses; 2019 Oct; 11(11):. PubMed ID: 31683550
[TBL] [Abstract][Full Text] [Related]
23. NK Cells Accumulate in Infected Tissues and Contribute to Pathogenicity of Ebola Virus in Mice.
Fausther-Bovendo H; Qiu X; He S; Bello A; Audet J; Ippolito G; Wong G; Kobinger G
J Virol; 2019 May; 93(10):. PubMed ID: 30814283
[TBL] [Abstract][Full Text] [Related]
24. Proximity proteomics identifies novel function of Rab14 in trafficking of Ebola virus matrix protein VP40.
Fan J; Liu X; Mao F; Yue X; Lee I; Xu Y
Biochem Biophys Res Commun; 2020 Jun; 527(2):387-392. PubMed ID: 32327259
[TBL] [Abstract][Full Text] [Related]
25. Ebola Immunity: Gaining a Winning Position in Lightning Chess.
Ploquin A; Zhou Y; Sullivan NJ
J Immunol; 2018 Aug; 201(3):833-842. PubMed ID: 30038036
[TBL] [Abstract][Full Text] [Related]
26. Intra-host dynamics of Ebola virus during 2014.
Ni M; Chen C; Qian J; Xiao HX; Shi WF; Luo Y; Wang HY; Li Z; Wu J; Xu PS; Chen SH; Wong G; Bi Y; Xia ZP; Li W; Lu HJ; Ma J; Tong YG; Zeng H; Wang SQ; Gao GF; Bo XC; Liu D
Nat Microbiol; 2016 Sep; 1(11):16151. PubMed ID: 27595345
[TBL] [Abstract][Full Text] [Related]
27. Differential requirements for FcγR engagement by protective antibodies against Ebola virus.
Bournazos S; DiLillo DJ; Goff AJ; Glass PJ; Ravetch JV
Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20054-20062. PubMed ID: 31484758
[TBL] [Abstract][Full Text] [Related]
28. Immune evasion in ebolavirus infections.
Audet J; Kobinger GP
Viral Immunol; 2015 Feb; 28(1):10-8. PubMed ID: 25396298
[TBL] [Abstract][Full Text] [Related]
29. Sequence analysis of the GP, NP, VP40 and VP24 genes of Ebola virus isolated from deceased, surviving and asymptomatically infected individuals during the 1996 outbreak in Gabon: comparative studies and phylogenetic characterization.
Leroy EM; Baize S; Mavoungou E; Apetrei C
J Gen Virol; 2002 Jan; 83(Pt 1):67-73. PubMed ID: 11752702
[TBL] [Abstract][Full Text] [Related]
30. A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism.
González-Hernández M; Hoffmann M; Brinkmann C; Nehls J; Winkler M; Schindler M; Pöhlmann S
J Virol; 2018 Jul; 92(13):. PubMed ID: 29669839
[TBL] [Abstract][Full Text] [Related]
31. Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection.
Iampietro M; Younan P; Nishida A; Dutta M; Lubaki NM; Santos RI; Koup RA; Katze MG; Bukreyev A
PLoS Pathog; 2017 May; 13(5):e1006397. PubMed ID: 28542576
[TBL] [Abstract][Full Text] [Related]
32. Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection.
Hill-Batorski L; Halfmann P; Marzi A; Lopes TJ; Neumann G; Feldmann H; Kawaoka Y
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S329-35. PubMed ID: 26209680
[TBL] [Abstract][Full Text] [Related]
33. An Intrinsically Disordered Peptide from Ebola Virus VP35 Controls Viral RNA Synthesis by Modulating Nucleoprotein-RNA Interactions.
Leung DW; Borek D; Luthra P; Binning JM; Anantpadma M; Liu G; Harvey IB; Su Z; Endlich-Frazier A; Pan J; Shabman RS; Chiu W; Davey RA; Otwinowski Z; Basler CF; Amarasinghe GK
Cell Rep; 2015 Apr; 11(3):376-89. PubMed ID: 25865894
[TBL] [Abstract][Full Text] [Related]
34. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
35. Budding of Ebola Virus Particles Requires the Rab11-Dependent Endocytic Recycling Pathway.
Nanbo A; Ohba Y
J Infect Dis; 2018 Nov; 218(suppl_5):S388-S396. PubMed ID: 30476249
[TBL] [Abstract][Full Text] [Related]
36. Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors.
Paquin-Proulx D; Gunn BM; Alrubayyi A; Clark DV; Creegan M; Kim D; Kibuuka H; Millard M; Wakabi S; Eller LA; Michael NL; Schoepp RJ; Hepburn MJ; Hensley LE; Robb ML; Alter G; Eller MA
Front Immunol; 2021; 12():682120. PubMed ID: 34093585
[TBL] [Abstract][Full Text] [Related]
37. The pathogenesis of Ebola hemorrhagic fever.
Takada A; Kawaoka Y
Trends Microbiol; 2001 Oct; 9(10):506-11. PubMed ID: 11597453
[TBL] [Abstract][Full Text] [Related]
38. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.
Warfield KL; Swenson DL; Olinger GG; Kalina WV; Aman MJ; Bavari S
J Infect Dis; 2007 Nov; 196 Suppl 2():S430-7. PubMed ID: 17940980
[TBL] [Abstract][Full Text] [Related]
39. Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin.
Gustin JK; Bai Y; Moses AV; Douglas JL
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S181-90. PubMed ID: 25821226
[TBL] [Abstract][Full Text] [Related]
40. Ebola virus disease: An emerging and re-emerging viral threat.
Rojas M; Monsalve DM; Pacheco Y; Acosta-Ampudia Y; Ramírez-Santana C; Ansari AA; Gershwin ME; Anaya JM
J Autoimmun; 2020 Jan; 106():102375. PubMed ID: 31806422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
